Human rotavirus vaccine

Human neonatal rotavirus vaccine (RV3-BB) targets rotavirus from birth

BACKGROUND A strategy of administering a neonatal rotavirus vaccine at birth to target early prevention of rotavirus gastroenteritis may address some of the barriers to global implementation of a rotavirus vaccine. METHODS We conducted a randomized, double-blind, placebo-controlled trial in Indonesia to evaluate the efficacy of an oral human neonatal rotavirus vaccine (RV3-BB) in preventing r...

Rotarix (RIX4414): an oral human rotavirus vaccine.

Rotavirus is the most common cause of severe gastroenteritis in children younger than 3 years of age worldwide. New rotavirus vaccine candidates were required to confer early protection against the most common rotavirus serotypes and to be well tolerated and not associated with intussusception. RIX4414 is a human-attenuated G1(P8) oral rotavirus vaccine administered in two doses at approximatel...

The human rotavirus vaccine Rotarix™ in infants

An integrated analysis of safety and reactogenicity data was undertaken for 28 randomized, placebo-controlled, double-blind Phase II and III trials (DBRCTs) of the oral live-attenuated human rotavirus vaccine, Rotarix™ (GlaxoSmithKline Vaccines). Healthy infants aged 6-20 wk received 2 or 3 doses of vaccine (n=56562) or placebo (n=45512) at 4- to 8-wk intervals. Solicited adverse events (AEs) w...

Rotavirus Vaccine Workshop Held

More than 125 participants from at least 15 countries attended the Fifth Rotavirus Vaccine Workshop at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, October 16-17, 1995. Rotavirus has emerged as the most important cause of severe diarrhea in children worldwide. It is a problem not only in developing countries, where it kills an estimated 870,000 children each year, b...

Rotarix rotavirus vaccine, live